trending Market Intelligence /marketintelligence/en/news-insights/trending/efghkn1g64vrmjmdje9nog2 content esgSubNav
In This List

Portola Pharmaceuticals chief commercial/business officer resigns

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Portola Pharmaceuticals chief commercial/business officer resigns

Portola Pharmaceuticals Inc. said Tao Fu resigned as executive vice president and chief commercial and business officer, effective Sept. 21, to pursue other opportunities.

South San Francisco, Calif.-based Portola said that Interim co-President and CFO Mardi Dier will lead its commercial activities, including the ongoing launches of blood disorder therapies Andexxa and Bevyxxa.

Fu will remain as a consultant until March 1, 2019, to assist in the transition.

The company said in a Sept. 7 news release that it has hired an executive search firm for recruiting a new CEO and chief commercial officer. Portola's CEO retired in August.

Portola is a biopharmaceutical company that develops and commercializes therapeutics relating to blood clotting and other blood disorders.